Details of the Drug
General Information of Drug (ID: DMEKU71)
Drug Name |
Dodeca-2E,4E-dienoic acid isobutylamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
UNII-5F4WO3BVS9; dodeca-2E,4E-dienoic acid isobutylamide; N-isobutyl-(2E,4E)-dodecadienamide; N-Isobutyldodeca-trans-2,4-dienamide; 5F4WO3BVS9; CHEMBL426912; CHEBI:70101; 2,4-Dodecadienamide, N-(2-methylpropyl)-, (2E,4E)-; Kalecide; Dodecatetraenoic acid isobutylamide, (2E,4E)-; AC1O5Y9Z; (2E,4E)-N-(2-methylpropyl)dodeca-2,4-dienamide; SCHEMBL2262688; MolPort-005-944-951; BBRMJCAPNGJKEM-AQASXUMVSA-N; BDBM50212599; ZINC36294914; 2,4-(E,E)-Dodecadienoylisobutylamide; MCULE-7934862818; (E,E)-N-Isobutyl-2,4-dodecadienamide
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 251.41 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 5.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 10 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||